Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TUMS turns 75

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline is rolling out new Tums Smoothies in Cocoa & Crème flavor to celebrate the brand's 75th birthday, the firm announces Nov. 14. GSK said in June it was changing the Smooth Dissolve brand name to Smoothies (1"The Tan Sheet" June 13, 2005, p. 6). The flavor is the category's first venture into chocolate, according to the firm, and the SRP on a 60-count bottle is $4.90. GSK also unveils Tums Smoothies "Take Out" packs, which hold 12 tablets in an "on the go" container for $1.56. The packs are sold in peppermint, assorted tropical fruit, assorted fruit and cocoa & crème...

You may also be interested in...

NACDS Marketplace In Brief

Bayer Rapid Headache Relief: TV spot supporting the launch of Bayer Rapid Headache Relief claims the product "releases medicine" five times faster than Tylenol Gels. The spot broke on national network and cable channels May 31. The product, which contains 500 mg aspirin/65 mg caffeine, was featured by Bayer at the National Association of Chain Drug Stores Marketplace in New Orleans June 5-7. A 50-count package retails for $5.25. The TV spot opens with a mother driving her children to soccer practice as an announcer says, "The number one cause of headaches: everyday life. Want fast relief? Introducing new Bayer Rapid Headache Relief." A message superimposed over an image of the Bayer and Tylenol Gel capsules dissolving notes the elapsed release time is 27 seconds for Bayer's product and 133 seconds for Tylenol...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts